SUDEEPPHRM Share Price | Sudeep Pharma Ltd Stock Analysis & Recommendation

Q: When is the next results date for Sudeep Pharma Ltd?

The next results date for Sudeep Pharma Ltd is scheduled for 21 May 2026.

Q: Should I buy, sell or hold Sudeep Pharma Ltd?

Based on the current analysis of Sudeep Pharma Ltd, it would be advisable to hold your position in the company. The firm demonstrates high management efficiency with a notable return on equity (ROE) of 19.6%, indicating effective use of equity capital. Additionally, the company has a strong ability to service its debt, reflected in a low Debt to EBITDA ratio of 0.68 times.Recent quarterly results show promising performance, with net sales reaching their highest at Rs 182.34 crore and a significant increase in profit before tax. However, it's important to note that the company has experienced poor long-term growth, with operating profit stagnating at an annual growth rate of 0% over the past five years.Despite the positive short-term financial results, the valuation appears expensive with a Price to Book Value of 8.6, which may raise concerns for potential investors. Given these factors, maintaining your current position seems prudent until there are clearer signs of sustainable growth or a more favorable valuation.

Results Declared: Sudeep Pharma has declared results on 21 May 2026! Click here to unlock the latest financial performance

Technical Trend Update: Sudeep Pharma witnessed a change in Technical Grade on 22 May 2026. Click here to discover latest technical change!

Mojo Score Change: Sudeep Pharma has changed its score on 22 May 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.08 lacs (460.18%) Volume

Shareholding (Mar 2026)

FII

1.55%

Held by 13 FIIs

DII

18.11%

Held by 10 DIIs

Promoter

76.15%

When is the next results date for Sudeep Pharma Ltd?

15-May-2026

The next results date for Sudeep Pharma Ltd is 21 May 2026.

View full answer

Should I buy, sell or hold Sudeep Pharma Ltd?

23-May-2026

Which are the latest news on Sudeep Pharma?

24-May-2026

Sudeep Pharma Ltd is Rated Hold by MarketsMOJO
Sudeep Pharma Q4 FY26: Strong Revenue Growth But Premium Valuation Raises Concerns

Why is Sudeep Pharma Ltd falling/rising?

25-May-2026

As of 24-May, Sudeep Pharma Ltd's stock price is rising, currently at 671.65, reflecting a 0.54% increase. The stock has shown strong upward momentum, outperforming its sector, with significant investor interest and solid financial performance contributing to its gains.

View full answer

Compare Sudeep Pharma with Similar Stocks

Blue Jet Health Sanofi India Akums Drugs

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 0%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.68 times

Poor long term growth as Operating profit has grown by an annual rate 0% of over the last 5 years

Positive results in Mar 26

With ROE of 19.6, it has a Very Expensive valuation with a 8.6 Price to Book Value

Majority shareholders : Promoters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 7,963 Cr (Small Cap)

P/E

44.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.10

Return on Equity

19.15%

Price to Book

8.57

Revenue and Profits:

Net Sales:

182 Cr

(Quarterly Results - Mar 2026)

Net Profit:

49 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

8.71%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Sudeep Pharma for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Sudeep Pharma Ltd Upgraded to Hold on Improved Financials and Technicals

Sudeep Pharma Ltd has been assigned a Hold rating with a Mojo Score of 64.0, reflecting a notable upgrade from its previous ungraded status. This change, effective from 22 May 2026, is driven by significant improvements across four key parameters: financial trend, quality, valuation, and technicals. The company’s recent quarterly performance, alongside evolving market dynamics, has prompted this reassessment, positioning Sudeep Pharma as a cautiously optimistic pick within the Pharmaceuticals & Biotechnology sector.

Read full news article

Sudeep Pharma Ltd Technical Momentum Shifts Signal Mild Bullish Outlook

Sudeep Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. Recent technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, suggest a cautiously optimistic outlook for the stock, supported by positive price action and relative strength compared to the broader market.

Read full news article

Sudeep Pharma Ltd Quality Grade Upgrade Reflects Strengthened Business Fundamentals

Sudeep Pharma Ltd has recently seen its quality grade upgraded from 'Does Not Qualify' to 'Good' by MarketsMOJO, reflecting a marked improvement in its business fundamentals. This upgrade, announced on 22 May 2026, highlights enhanced operational efficiency, robust return ratios, and prudent debt management, positioning the small-cap pharmaceutical company favourably within its sector.

Read full news article

Announcements

No announcement available

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

33.98

Debt to EBITDA (avg)

0.72

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.65

Tax Ratio

23.58%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

19.67%

ROCE (avg)

24.88%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

8.57

EV to EBIT

36.72

EV to EBITDA

34.27

EV to Capital Employed

8.27

EV to Sales

11.84

PEG Ratio

Dividend Yield

ROCE (Latest)

22.53%

ROE (Latest)

19.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

RSI

No Signal

Bollinger Bands

Bullish

KST

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 14 Schemes (6.19%)

FIIs

Held by 13 FIIs (1.55%)

Promoter with highest holding

Riva Resources Private Limited (40.35%)

Highest Public shareholder

Nuvama Crossover Opportunities Fund - Series Iii (3.42%)

Individual Investors Holdings

3.11%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -11.20% vs 2.73% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -4.09% vs -9.65% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "80.17",
          "val2": "90.28",
          "chgp": "-11.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "28.89",
          "val2": "29.61",
          "chgp": "-2.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.97",
          "val2": "0.63",
          "chgp": "212.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "25.77",
          "val2": "26.87",
          "chgp": "-4.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.04%",
          "val2": "32.80%",
          "chgp": "3.24%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "168.06",
          "val2": "168.40",
          "chgp": "-0.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "61.27",
          "val2": "60.03",
          "chgp": "2.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.47",
          "val2": "1.99",
          "chgp": "74.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "54.95",
          "val2": "41.98",
          "chgp": "30.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.46%",
          "val2": "35.65%",
          "chgp": "0.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "258.34",
          "val2": "251.88",
          "chgp": "2.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "90.88",
          "val2": "86.49",
          "chgp": "5.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "3.24",
          "chgp": "26.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "81.82",
          "val2": "62.61",
          "chgp": "30.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "35.18%",
          "val2": "34.34%",
          "chgp": "0.84%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "642.26",
          "val2": "502.00",
          "chgp": "27.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "221.91",
          "val2": "189.95",
          "chgp": "16.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "5.85",
          "chgp": "29.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "172.89",
          "val2": "138.73",
          "chgp": "24.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.55%",
          "val2": "37.84%",
          "chgp": "-3.29%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

80.17

90.28

-11.20%

Operating Profit (PBDIT) excl Other Income

28.89

29.61

-2.43%

Interest

1.97

0.63

212.70%

Exceptional Items

0.00

Standalone Net Profit

25.77

26.87

-4.09%

Operating Profit Margin (Excl OI)

36.04%

32.80%

3.24%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -11.20% vs 2.73% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is -4.09% vs -9.65% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

168.06

168.40

-0.20%

Operating Profit (PBDIT) excl Other Income

61.27

60.03

2.07%

Interest

3.47

1.99

74.37%

Exceptional Items

0.00

Standalone Net Profit

54.95

41.98

30.90%

Operating Profit Margin (Excl OI)

36.46%

35.65%

0.81%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

258.34

251.88

2.56%

Operating Profit (PBDIT) excl Other Income

90.88

86.49

5.08%

Interest

4.10

3.24

26.54%

Exceptional Items

0.00

Standalone Net Profit

81.82

62.61

30.68%

Operating Profit Margin (Excl OI)

35.18%

34.34%

0.84%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

642.26

502.00

27.94%

Operating Profit (PBDIT) excl Other Income

221.91

189.95

16.83%

Interest

7.60

5.85

29.91%

Exceptional Items

0.00

Consolidate Net Profit

172.89

138.73

24.62%

Operating Profit Margin (Excl OI)

34.55%

37.84%

-3.29%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025

All Annual Results

Company CV

About Sudeep Pharma Ltd

Sudeep Pharma Ltd

Small Cap

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available